首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1654724

全球肺癌诊断市场 - 2025 - 2033

Global Lung Cancer Diagnostics Market - 2025-2033

出版日期: 2025年02月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球肺癌诊断市场规模达 49.4 亿美元，预计到 2033 年将达到 84.4 亿美元，2025-2033 年预测期内的复合年增长率为 6.18%。

肺癌诊断对于肺癌的早期发现、准确诊断和有效治疗至关重要，肺癌仍然是全球癌症相关死亡的主要原因之一。早期发现肺癌对于确定最佳治疗方案和提高存活率至关重要。使用了多种诊断方法，包括 CT 扫描、X 光和 PET 扫描等影像技术，以及生物标记测试和基因分析。

液体活检是一种较新的非侵入性技术，因识别癌症的基因突变和特定特征而越来越受欢迎。这些进步使得制定更个人化的治疗方案成为可能，例如标靶治疗或免疫疗法，这些方案在改善患者预后方面显示出良好的效果。

市场动态：

驱动因素与约束因素

肺癌发生率上升

肺癌发生率的上升是推动肺癌诊断市场成长的关键因素。随着全球病例数量持续增加，对有效和早期检测方法的需求也越来越大。肺癌仍然是最致命和最常见的癌症之一，主要是由于吸烟、空气污染和其他环境影响等因素造成的。

随着每年被诊断出罹患癌症的人数越来越多，对更早、更容易治疗的先进诊断工具的需求也显着增长。例如，根据美国癌症协会的数据，预计 2025 年将报告约 226,650 例新的肺癌病例。一般来说，SCLC约占所有肺癌病例的13%，而NSCLC约占87%。

随着肺癌病例数量的增加，医疗保健提供者和患者都在寻求更准确、更有效、更方便的诊断方法，以提高存活率。早期发现对于获得更好的结果至关重要，对低剂量 CT 扫描和生物标记测试等筛检工具的需求也日益增加。因此，肺癌病例数的增加是肺癌诊断市场发展的主要驱动力。

诊断测试费用高昂

诊断测试的高成本限制了人们获得先进技术的管道，尤其是在中低收入地区，这对肺癌诊断市场的成长构成了重大挑战。昂贵的诊断方法，例如液体活检、基因组检测和 PET 扫描，对于许多患者来说往往是经济上无法承受的，从而导致诊断延迟或依赖不太精确、更便宜的替代方法。

Lung cancer diagnostics are crucial for early detection, accurate diagnosis, and effective treatment of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Detecting lung cancer early is vital for determining the best course of treatment and improving survival rates. A variety of diagnostic methods are used, including imaging techniques like CT scans, X-rays, and PET scans, as well as biomarker testing and genetic analysis.

Liquid biopsy, a newer and non-invasive technology, is also gaining popularity for identifying genetic mutations and specific characteristics of the cancer. These advancements have made it possible to create more personalized treatment plans, such as targeted therapies or immunotherapies, which are showing promising results in improving patient outcomes.

Market Dynamics: Drivers & Restraints

Rising incidence of lung cancer cases

The rising incidence of lung cancer is a key factor driving the growth of the lung cancer diagnostics market. As the number of cases continues to increase worldwide, there's a greater need for effective and early detection methods. Lung cancer remains one of the deadliest and most common cancers, largely due to factors like smoking, air pollution, and other environmental influences.

With more people being diagnosed each year, the demand for advanced diagnostic tools to catch the disease at an earlier, more treatable stage has grown significantly. For instance, according to the American Cancer Society, it is estimated that about 226,650 new cases of lung cancer cases are expected to report in 2025. Lung cancer statistics typically encompass both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Generally, SCLC accounts for about 13% of all lung cancer cases, while NSCLC makes up approximately 87%.

As the number of lung cancer cases rises, both healthcare providers and patients are looking for more accurate, efficient, and accessible diagnostic options to improve survival rates. Early detection is essential for better outcomes, and there's an increasing need for screening tools like low-dose CT scans and biomarker testing. Thus, the growing number of lung cancer cases is a major driver for the lung cancer diagnostics market.

High Costs of Diagnostic Tests

The high cost of diagnostic tests poses a significant challenge to the growth of the lung cancer diagnostics market by restricting access to advanced technologies, especially in low- and middle-income regions. Expensive diagnostic methods, such as liquid biopsies, genomic testing, and PET scans, are often financially inaccessible to many patients, resulting in delayed diagnoses or reliance on less precise, more affordable alternatives.

Segment Analysis

The global lung cancer diagnostics market is segmented based on cancer type, diagnostic test type, product type, end-user, and region.

Treatment:

Biopsy segment is expected to dominate the global lung cancer diagnostics market share

The biopsy segment is expected to lead the lung cancer diagnostics market because it plays a vital role in accurately diagnosing lung cancer. Methods like needle biopsies, bronchoscopic biopsies, and surgical biopsies are essential for confirming the presence of cancer cells and determining the type and stage of the disease. Different biopsy tests are introduced by the companies to enhance the accuracy of the diagnostic procedures. For instance, in October 2023, Delfi Diagnostics introduced its first liquid biopsy test, fulfilling the company's long-standing goal of providing a blood-based screening tool for lung cancer. The Firstlook Lung test aims to offer a more accessible and convenient detection method, reaching a broader population compared to current standards.

Recent advancements in minimally invasive techniques, such as CT-guided needle biopsies and EBUS-guided biopsies, have made it easier to collect tissue samples with fewer risks, which has led to wider adoption in clinical practice. Companies are forming partnerships to widen the usage pof the existing tests and products. For instance, in January 2023, Agilent and Quest Diagnostics have partnered to broaden access to the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This FDA-approved, single-site premarket test serves as a companion diagnostic (CDx) to identify patients with advanced non-small cell lung cancer (NSCLC) who may benefit from treatment with adagrasib (brand name Krazati).

As precision medicine continues to gain importance, biopsies are key for genomic profiling and identifying biomarkers, which are crucial for selecting the most effective targeted therapies and immunotherapies. This ability to support personalized treatment is a major factor driving the dominance of the biopsy segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global lung cancer diagnostics market share

North America is expected to maintain a dominant position in the global lung cancer diagnostics market, driven by its advanced healthcare infrastructure and high lung cancer incidence. The region's access to cutting-edge diagnostic technologies, such as advanced imaging systems, liquid biopsies, and genomic testing, enables early and accurate detection of lung cancer, which is crucial for improving patient outcomes.

Growing awareness about the importance of early lung cancer screening, along with a rising emphasis on precision medicine, has fuelled the demand for effective and personalized diagnostic solutions. Moreover, the significant investments in healthcare research for diagnostic procedures, ensure that patients have greater access to the latest diagnostic tools. For instance, in October 2023, DELFI Diagnostics, Inc., a company focused on accessible blood-based tests to improve cancer detection, has announced the initial commercial launch of FirstLook Lung. This blood test provides a convenient, accurate, and personalized result by assessing the likelihood of detecting lung cancer through low-dose CT (LDCT), boasting an impressive negative predictive value (NPV) of 99.7%. These factors hold the region in the dominant position in the lung cancer diagnostics market.

Competitive Landscape

The major global players in the lung cancer diagnostics market include Quest Diagnostics Incorporated, Biodesix, Lepu Medical Technology (Beijing)Co., Ltd., DSS Imagetec, Abbott, Guardant Health, Intuitive Surgical, bioAffinity Technologies, Inc., Optellum Ltd and F. Hoffmann-La Roche Ltd. among others.

Key Developments

In January 2025, Monitor Corporation has begun selling its lung cancer diagnosis software in Japan through a partnership with Doctor-NET, a Japanese digital healthcare provider.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Lung Cancer Diagnostics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Cancer Type
3.2. Snippet by Diagnostic Test Type
3.3. Snippet by Product Type
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising incidence of lung cancer cases
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Cancer Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Non-small Cell Lung Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Small Cell Lung Cancer

7. By Diagnostic Test Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
7.2. Biopsies*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Imaging Tests
7.4. Molecular Testing
7.5. Others

8. By Product Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.1.2. Market Attractiveness Index, By Product Type
8.2. Instruments*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Consumables

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

12.1. F. Hoffmann-La Roche Ltd*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
  - 12.1.2.1. Product Description
  - 12.1.2.2. Product Key Performance Indicators (KPIs)
  - 12.1.2.3. Historic and Forecasted Product Sales
  - 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
  - 12.1.3.1. Company Revenue's
  - 12.1.3.2. Geographical Revenue Shares
  - 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
  - 12.1.4.1. Mergers & Acquisitions
  - 12.1.4.2. Key Product Development Activities
  - 12.1.4.3. Regulatory Approvals etc.
- 12.1.5. SWOT Analysis
12.2. Biodesix
12.3. Lepu Medical Technology (Beijing)Co., Ltd.
12.4. DSS Imagetec
12.5. Abbott
12.6. Guardant Health
12.7. Intuitive Surgical
12.8. bioAffinity Technologies, Inc.
12.9. Optellum Ltd
12.10. F. Hoffmann-La Roche Ltd.
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球肺癌诊断市场 - 2025 - 2033

Global Lung Cancer Diagnostics Market - 2025-2033

市场动态：

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

第五章：产业分析

第 6 章：按癌症类型

第 7 章：按诊断测试类型

第 8 章：依产品类型

第 9 章：按最终用户

第 10 章：按地区

第 11 章：竞争格局

第 12 章：公司简介

第 13 章：附录